Added to YB: 2026-02-24
Pitch date: 2026-02-22
INVA [bullish]
Innoviva, Inc.
-5.37%
current return
Author Info
FluentInQuality invests in high-quality businesses that generate steady and sustainable cashflows, proven track records, and the potential to act as a true compounding machines over the long run. Sign up for the newsletter.
Company Info
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.
Market Cap
$1.7B
Pitch Price
$23.46
Price Target
N/A
Dividend
N/A
EV/EBITDA
7.67
P/E
15.34
EV/Sales
3.96
Sector
Pharmaceuticals
Category
growth
6 High-Quality Stocks With 20%+ ROIC Wall Street Ignores - Innoviva, Inc.
INVA: Healthcare capital allocator earning high-margin royalties from partnered respiratory products, reinvesting FCF into commercial-stage assets vs risky R&D. Diversified portfolio reduces binary biotech risk. Asset-light model + balance sheet strength enable countercyclical M&A when healthcare valuations compress.
Read full article (2 min)